Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic
Association Between Second Progression-free Survival (PFS2) and Overall Survival in Metastatic Castration-resistant Prostate Cancer - European Urology
Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive
Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials - European Journal of Cancer
Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology
Correlations of survival with progression-free survival, response rate, and disease control rate in advanced biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy | British Journal of Cancer
Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive
Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations - ESMO Open
Progression-free survival and overall survival curves for all patients... | Download Scientific Diagram
Progression free survival (a) and overall survival (b) curves... | Download Scientific Diagram
Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors - Journal of Thoracic Oncology
A) Disease-free survival, (B) progression-free survival and (C)... | Download Scientific Diagram
Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD-1/PD-L1 Antibodies - Journal of Thoracic Oncology
Estimating progression-free survival in patients with glioblastoma using routinely collected data | SpringerLink
Predicting Overall Survival and Progression-Free Survival Using Tumor Dynamics in Advanced Breast Cancer Patients | Semantic Scholar
Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy – The GCIG
Relationship between progression‐free survival and overall survival in patients with advanced non‐small cell lung cancer treated with anticancer agents after first‐line treatment failure - Suzuki - 2015 - Asia-Pacific Journal of Clinical
PPT - Overall Survival and Progression-Free Survival PowerPoint Presentation - ID:4064400
Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy | BMC Cancer | Full
Progression-free survival and overall survival in all patients. | Download Scientific Diagram
Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta-Analysis of 37 Trials - ScienceDirect
Kaplan-Meier survival curves of progression-free survival and overall... | Download Scientific Diagram
Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined - Annals of Oncology
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open
Extrapolation from Progression-Free Survival to Overall Survival in Oncology
